Core Insights - Prelude Therapeutics has appointed Katina Dorton to its Board of Directors, effective October 17, 2025, bringing over 30 years of experience in healthcare and life sciences [1][2] - Ms. Dorton will also take over as Audit Committee Chair, succeeding Mardi C. Dier, who has served on the board since August 2020 [3] - Prelude Therapeutics is focused on advancing its precision oncology drug candidates and aims to create significant shareholder value [2][3] Company Overview - Prelude Therapeutics is a clinical-stage precision oncology company developing innovative medicines for cancer patients with high unmet needs [4] - The company's pipeline includes several novel drug candidates, such as first-in-class SMARCA2 and KAT6A degraders, and it is also researching next-generation degrader antibody conjugates [4] - Prelude's mission is to extend the promise of precision medicine to every cancer patient in need [4]

Company Participation - Prelude Therapeutics will participate in the Citizens Life Sciences Conference in New York on May 7, 2025 [1] - The company's CEO, President and Chief Medical Officer, and Chief Scientific Officer will engage in a fireside chat during the conference [2] Company Overview - Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative medicines for cancer patients with high unmet needs [3] - The company's pipeline includes first-in-class SMARCA2 degraders and a potentially best-in-class CDK9 inhibitor, along with next-generation degrader antibody conjugates [3] - Prelude aims to extend the promise of precision medicine to all cancer patients in need [3]

Company Participation - Prelude Therapeutics will participate in the Citizens Life Sciences Conference in New York on May 7, 2025 [1] - The participation will include a fireside chat featuring key executives: Kris Vaddi, Jane Huang, and Peggy Scherle [2] Company Overview - Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative medicines for cancer patients with high unmet needs [3] - The company's pipeline includes first-in-class SMARCA2 degraders and a potentially best-in-class CDK9 inhibitor [3] - Prelude is also working on next-generation degrader antibody conjugates (Precision ADCs) in collaboration with partners [3]